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Optimizing Cost and Data Entry for Assignment of Patients to Clinical Trials Using
Analytical and Probabilistic Web-Based Agents

Bhavesh Dineshbhai Goswami

ABSTRACT

A clinical trial is defined as a study conducted on a group of patients to determine the
effect of a treatment. Assignment of patients to clinical trials is a data and labor intensive
task. Usually, medical personnel manually check the eligibility of a patient for a clinical
trial based on the patient’s medical history and current medical condition. According to
studies, most clinical trials are under-enrolled which negatively affects their
effectiveness. We have developed web-based agents that can test the eligibility of
patients for many clinical trials at once. We have tested various heuristics for optimizing
cost and data entry needed in assigning patients to clinical trials. Testing eligibility of a
patient for many clinical trials is only feasible if it is cost and data entry efficient. Agents
with different heuristics were then tested on data from current breast cancer patients at
the Moffitt Cancer Center. Results with different heuristics are compared with each other
and with that of the clinicians. It is shown that cost savings are possible in clinical trial
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assignment. Also, less data entry is needed when probabilistic agents are used to reorder
questions.
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Chapter 1
Introduction
1.1

Introduction

A clinical trial is an experimental research study that evaluates a specific new treatment
for a specific population of patients. The trial protocol is a rulebook which clearly
identifies the criteria for a patient to be eligible for the trial. The criteria is based on the
medical history and the present medical condition of the patient. Some criteria are general
information such as the age and sex of the patient while others requires specific tests be
done to determine if the patient matches them. Eligibility is usually checked manually by
a clinician, nurse or trial coordinator. In the absence of enough information to determine
the eligibility of a patient, clinicians order tests needed to obtain the required information.
Each test has some cost associated with it and studies show that if tests are reordered
correctly, cost savings are possible [1, 11, 14]. Although clinicians can potentially reduce
costs by ordering inexpensive tests first, test reordering is a complex optimization
problem which has many parameters like the actual cost of the test, number of eligibility
criterion decided by it, number of protocols in which the test is needed and the
probability of the test resulting in an eligibility decision for the patient.
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1.2

Significance

Cancer is one of the major causes of death in United States resulting in 550,000 deaths
annually. Cancer treatment is an active research area. Clinical trials are used to research
new treatments. Accrual of patients to these clinical trials is of the utmost importance for
the success of a trial. At any one time there are many active trials, and keeping track of
them becomes a difficult task. Studies show that clinicians sometimes miss up to 50% to
60% of the eligible patients [11, 22, 33]. In such a scenario, having a web-based agent
with a central database of clinical trials that can be accessed through the internet by any
willing institute can drastically improve accrual of patients. It may also ease the process
of trial sharing among various institutes, which is difficult otherwise.
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Chapter 2
Previous Work
2.1

Software Agents

A software agent is defined as an autonomous software entity that can interact with its
environment to accomplish certain objectives without any direct input or supervision
from its user. Software agents are used in a variety of fields like VLSI design, search
engines, e-commerce applications, business processes, medical research, etc. Earlier use
of AI in medical domains was primarily through expert systems for diagnosis and
treatment suggestions. The primary difference between expert system and agent is that
the agent changes dynamically according to the changes in its environment and that many
agents can work together to accomplish certain task(s). The analytical and probabilistic
agents, which we developed, dynamically change their heuristic parameter values as new
information is received. The analytical agent modifies the rule graphs and cost
information when it acquires new information, while the probabilistic knowledge base is
updated on acquisition of new information, which dynamically changes the heuristic
parameter values of the probabilistic agent. Also the analytical and probabilistic agents
can work together to reorder the questions and assign patients to clinical trials. Due to the
above facts, we term them as agents.
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2.2

History

Research in the use of Artificial Intelligence for medical diagnosis has been conducted
since the early seventies. A variety of expert systems were developed for diagnosis and
treatment of various diseases. The MYCIN system for diagnosis of bacterial diseases was
developed by Shortliffee and colleagues [13]. It evolved from a chemical expert system
called DENDRAL [8, 24, 25]. It was a rule-based system with if-then rules using the
backward chaining process. The system gathered information about the patient and
provided treatment recommendations with explanations of how the conclusion was
reached. MYCIN was found to be fairly accurate in the experiments conducted, which
led to the development of various other medical expert systems. EMYCIN [7] was
developed from MYCIN. It was a generic expert system shell where rules from any
domain could be added to the knowledge base. A lung disease knowledge base was
developed using EMYCIN and the resultant system was called PUFF [26]. An expert
system called NEOMYCIN [9] was developed to train doctors by presenting them with
practice cases, getting their diagnosis and correcting them when they made mistakes.
2.3

Similar Systems

Researchers have adopted many different approaches for systems to assign patients to
clinical trials. A system called AIDS [28] was developed to assign patients to HIV
clinical trial treatment protocols. It used Bayesian belief networks to manage uncertainty.
It has a protocol driven mode, where each patient’s probability of eligibility is checked
automatically for a new clinical trial protocol using the data patient has. EON [30] was
made with reusability as a high priority. Thus they made four reusable basic components
of the system. The knowledge base could be generated for any protocol based therapy.
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ONCODOC [4, 5, 6, 19, 20] was developed to “enhance the accrual of patients in the
best care plan.” It had non-metastatic breast cancer protocols encoded as decision trees.
The goal was to enhance the usability of the system by providing flexibility in the
interpretation of the results by clinicians. Clinicians incrementally assign values to the
decision parameters while navigating through the decision tree. Thus it is halfway
between knowledge representation and a static written description and allows both formal
and informal aspects of the protocols to be implemented. It means that a clinician can
make an explicit decision if a test result is borderline or can navigate through the
remaining decision tree to see the underlying logic and make his decision. An important
drawback of using decision trees is that you cannot test a patient for multiple trials at
once. One will have to test a patient separately for each trial, and thus the time consumed
will increase drastically when the patient’s eligibility is checked for many clinical trials.
A system to assign patients to clinical trials was designed by Papaconstantinou
and colleagues [10] using Bayesian networks. They were successful in implementing
three clinical trials but concluded that the complexity of the Bayesian network immensely
increased when new trials were being added. Another drawback was the difficulty in
getting the prior probability relationships between different nodes of the network. Also,
propagation of probabilities with data evidence was very slow. Another system DIAVAL
[8] was also a Bayesian expert system for echocardiaography. It had the same problems
discussed above. Smith and McNeely [2, 31] built an expert system to reorder tests for
laboratory investigations of patients for general clinical problems. They used the
ACQUIRE suite of expert system tools to design this system. Their results shows that the
laboratory costs were reduced from mean $232 to $194 on tested patients.
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Chapter 3
System Design
3.1

System Overview

The system is divided into three main parts (a) Knowledge entry system, (b) Agent and,
(c) Testing system. Nikiforou [36] implemented the knowledge entry system. It is a webbased system that has user-friendly interface for encoding the clinical trials into a form
that is understood by the agents. Fletcher, Kokku [33] and colleagues have built the initial
agent for matching of patients to clinical trials. We modified the way cost was dealt with
in the system and conducted systematic experiments to evaluate the cost-savings by the
system. We also added the probabilistic agents to the system and conducted experiments
to compare the results. Figure 1 represents the basic structure of the system.
As shown in Figure 1, the user interacts with the system through the web-based
interface. A user can access old patient data, add new patients and enter data for existing
patients. Each time new information is obtained about the patient, her eligibility is
checked for the protocols selected. The patient is eligible, ineligible or more information
is required to decide on eligibility for a particular protocol. If more information is needed
to determine patient’s eligibility, the probabilistic agent calculates the eligibility
probability based on the current data of the patient and probabilistic knowledge base of
the system.
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Testing system

Agent
Patient database

User

User Interface

Explanation sub-system

Knowledge Base

Agent for assigning patients
to clinical trials

General knowledge and
implication
Domain specific
knowledge

Reordering Agents

Probabilistic

Probabilistic Knowledge

Analytical

Knowledge entry system

Figure 1: System Architecture

The system augments its probabilistic knowledge base by gathering information
entered for the current patients and its effect on the eligibility of the patient. After
checking eligibility, if the patient has protocols for which eligibility is not yet decided
upon, the reordering subsystem reorders the relevant questions using analytical and
probabilistic agents. At all times, the system has an explanation subsystem which can
provide an explanation for system’s decisions. More protocols can be added to the system
using the knowledge entry system. The testing system is used to test new heuristics by
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creating many new patients and testing the effectiveness of the system without human
intervention.
3.2

Knowledge Representation

The system incorporates domain knowledge in the form of medical tests, questions and
eligibility criteria. A test can be entered into the system with its name and cost. A list of
questions that are answered by that test are then entered. For example, as shown in Figure
2, Mammogram test answers questions i) What is the cancer stage? ii) Does the patient
have invasive cancer? Clinical trial protocols can then be entered into the system, which
are essentially a set of rules composed of the entered questions. The eligibility of the
patient for a particular protocol can then be tested using the agent. There is a web-based
interface to accomplish all these tasks.

General Questions

Cost: $0
Female

What is patient’s sex?

Male

What is patient’s age?

Mammogram

Cost: $150
I II III IV

What is the cancer stage?
Does the patient have invasive cancer?

Yes

CT scan (Head)

No

Unknown

No

Unknown

Cost: $850

Are there any symptoms of metastatic
disease in brain?

Yes

Figure 2: Example of Tests and Questions
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3.2.1 Medical Tests
Medical tests that are performed on patients to obtain information needed to determine
their eligibility are entered into the system along with the cost incurred to perform that
test. Each test, when performed, gives us information about the patient which is used to
determine her eligibility. This information is stored in the form of questions.
3.2.2 Questions
A question can be any of the three forms: (a) Yes/No, (b) Multiple choice and (c)
Numeric. A Yes/No question is the one where the answer to the question is yes, no or
unknown. Similarly, multiple choice questions have a list of two or more answers to
select the answer from. A numeric question has some numeric value as its answer. Figure
2 shows some tests and the questions associated with them.
3.2.3 Eligibility Criteria
The clinical trial eligibility criteria is essentially a logical expression of questions. Figure
3 shows an eligibility criteria and the corresponding logical expression. The system keeps
asking for data until either the expression in Figure 3(a) is TRUE or the expression in
Figure 3(b) is FALSE, which means that the patient is eligible or ineligible respectively.
For example, let’s assume that a patient’s eligibility is checked for the given trial which
has the eligibility criteria shown in Figure 3.
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1.
2.
3.
4.

Female of age 18 to 50 years.
Must be postmenopausal or using contraceptive.
Should not have metastatic disease in brain.
Cancer should not be invasive.

(a) Acceptance Expression
sex = FEMALE AND
age 18 AND
age 50 AND
{ postmenopausal = YES OR use_contraceptive = YES} AND
invasive_cancer = NO AND
brain_metastatic = NO


(b) Rejection Expression
sex = MALE OR
age 18 OR
age 50 OR
{ postmenopausal = NO AND use_contraceptive = NO} OR
invasive_cancer = YES OR
brain_metastatic = YES


Figure 3: Eligibility Criteria and its Acceptance and Rejection Expressions

Assume the system already has the data that the patient is female and that she is
postmenopausal. The remaining pertinent information to be obtained is (a) Age, (b) If
there is metastatic disease in the head and (c) If cancer is invasive. We do not need to
perform any tests to know a patient’s age so that information is free to us. On the other
hand, we need to perform a mammogram to check if the cancer is invasive and it costs
$150. Similarly, to check if there is metastatic disease in brain, we need to perform a CT
scan of the head, which costs $850. The cost optimization problem here is to see if it is
10

more beneficial to order a CT scan of the head or a mammogram. A mammogram looks
like a better alternative at the first glance as it costs much less then CT scan. However
there are other issues which are important too.
For example if most patients have invasive cancer, then it will be more efficient to
go for a CT scan, even though it is costs more, as the probability of a patient having
invasive cancer is high and it requires us to do a CT scan anyways after a mammogram is
performed. Also, when one tests for multiple protocols at once, many protocols might
need information which can be obtained from a single test, so that test gets priority. Thus
test ordering is a complex optimization task. The system keeps asking questions with
continued reordering until it can either determine that the acceptance expression is TRUE
or rejection expression is TRUE.
3.3

Algorithm

As described above, the system stores eligibility criteria of different trials in the form of
rules which are described as logical expressions of different questions. While computing
eligibility we store the rules in the form of nodes.
postmenopausal
= YES

age

age



use_contraceptive
= YES

OR

50

18

invasive_cancer
= YES

sex = Female

brain_metastatic
= YES
AND

Figure 4: Acceptance Expression Graph
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postmenopausal
= NO

age

age


use_contraceptive
= NO

AND

50

18

invasive_cancer
= NO

sex = Male

brain_metastatic
= NO
OR

Figure 5: Rejection Expression Graph

Two graphs are created, one for the acceptance expression and the other for the
rejection expression. The base node of the acceptance expression graph is the AND node
which represents the eligibility of a patient. It represents the conjunction of conditions
that are needed to be satisfied in order for a patient to be eligible for a protocol. Figure 4
shows the acceptance expression graph for eligibility criteria defined in Figure 3. Figure
5 is the rejection expression which represents the ineligibility criteria. The base node of
this graph is an OR node. The OR node represents a disjunction of conditions that rule
out a patient for a trial. The patient is eligible if the AND node of the acceptance
expression is TRUE, ineligible if the OR node of the rejection expression is TRUE and
the eligibility is not decided if neither of them is true. Only one of them can be TRUE at a
time for a given patient. The system will keep asking questions until one of the base
nodes is determined to be TRUE.
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3.3.1 Test Reordering
Analytical and probabilistic agents are used to reorder tests for the optimization of cost
and data entry. Analytical heuristics are based on test cost and the structure of the
rejection and acceptance expressions. Probabilistic agents use probabilistic data
accumulated over time by the system.
3.3.1.1 Analytical Reordering Agent
The analytical reordering agent uses three heuristic parameters to reorder tests. The first
parameter is the most fundamental one, which is the cost of a test. The more expensive
the test, the less likely it is for the system to obtain information associated with that test.
Less expensive tests get priority over the more expensive ones. Although this heuristic
looks straightforward, it has inherent drawbacks. For example imagine a scenario where
the agent has to decide between ordering two tests, test A and test B, where test B costs
twice as much as test A. Although the first thought would be to order test A ahead of test
B, that may not always be the case. Imagine a scenario where test A’s results are almost
always favorable for the patients, and almost no patient gets ruled out of a protocol due to
test A’s results. In such a scenario it will be more efficient to order test B ahead of test A.
When a patient is tested for multiple trials at once, a certain test might be needed to
determine eligibility for more than one trial. That is the second heuristic parameter. The
number of clinical trials that need a particular test be done, to determine the eligibility, is
taken as a heuristic parameter. The probability of a test being ranked highest is linearly
proportional to the number of trials that need it.
The third heuristic parameter is the number of clauses that include questions
answered by that test in the acceptance expression. To calculate this, the acceptance
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expression needs to be converted into Disjunctive Normal Form (DNF). Converting a
graph into DNF can take a considerable amount of processing time if the graph has many
OR nodes.
For example consider a simple expression (a ∨ b ∨ c) ∧ (e ∨ f ∨ g) ∧ (h ∨ i ∨ j)
with nine AND nodes and 1 OR node. After converting it into DNF the expression looks
like that in Figure 6

(a ∧ e ∧ h) ∨ (a ∧ e ∧ i) ∨ (a ∧ e ∧ j) ∨ (a ∧ f ∧ h) ∨ (a ∧ f ∧ i) ∨ (a ∧ f ∧ j) ∨
(a ∧ g ∧ h) ∨ (a ∧ g ∧ i) ∨ (a ∧ g ∧ j) ∨ (b ∧ e ∧ h) ∨ (b ∧ e ∧ i) ∨ (b ∧ e ∧ j) ∨
(b ∧ f ∧ h) ∨ (b ∧ f ∧ i) ∨ (b ∧ f ∧ j) ∨ (b ∧ g ∧ h) ∨ (b ∧ g ∧ i) ∨ (b ∧ g ∧ j) ∨
(c ∧ e ∧ h) ∨ (c ∧ e ∧ i) ∨ (c ∧ e ∧ j) ∨ (c ∧ f ∧ h) ∨ (c ∧ f ∧ i) ∨ (c ∧ f ∧ j) ∨
(c ∧ g ∧ h) ∨ (c ∧ g ∧ i) ∨ (c ∧ g ∧ j)
Figure 6: Expansion of CNF to DNF

As shown in Figure 6, the expression now has 27 AND nodes and one OR node. For
large expressions, this conversation takes considerable computing time and thus can be a
drawback. After the conversion, for each test, the number of clauses that depend on a
question belonging to that test is calculated. The tests that are needed in more clauses get
priority.
After the system gets any new information, it regenerates the graphs and
recalculates heuristics values. After calculating all three parameters of all tests, the agent
does a linear combination of the parameter values and orders the tests using it.
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3.3.1.2 Probabilistic Reordering Agent
Most people who have used a probabilistic approach towards expert systems or agents
have used Bayesian Networks. There are many inherent problems with this approach and
the prime ones are: (a) Bayesian Networks are very complex and it takes a lot of time to
build new networks when new trials are added (b) It is difficult to get initial relational
probabilities between nodes of the network (c) It takes a lot of computational time to
modify the conditional probability between nodes of the network in the wake of new
evidence [10, 15]. In spite of the above drawbacks, they also have some critical
advantages over analytical rule-based systems. The most important advantage
probabilistic systems have is their ability to estimate eligibility probability in the absence
of some information. Rule based systems cannot estimate the probability even in the
absence of a single piece of information. Consider a protocol which has 20 eligibility
rules, and 19 of them are met, which seemingly makes it likely for a patient to be eligible.
A rule based system will still not be able to predict anything about the probability of the
patient’s eligibility while a probabilistic system can estimate the eligibility of the patient
using the prior probabilities that the system has. Probability estimation becomes
important in certain cases, especially when you have many trials. The Moffitt Cancer
Center at USF has about 15 active breast cancer trials at once. It is time-consuming and
expensive to test patients for all trials. Thus rather than testing the patients for all trials,
we can just test her eligibility for trials which show high initial eligibility probability. We
can also use probabilistic knowledge accumulated over time by the system to reorder the
tests.
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To attempt to exploit the advantages of the probabilistic systems and to avoid its
drawbacks, we used the probabilistic methods discussed below. The basic idea is to try to
classify a patient as ineligible as soon as possible. The idea is that if a patient is
ineligible, the information that is most likely to determine her ineligible should be
obtained first. This would optimize the data-entry needed to decide upon a patient’s
eligibility. The system gathers this probabilistic knowledge over time. For each question
in the system, it keeps a log of how many times a question is asked and how many times
a patient is ruled out for a particular trial after that question is answered. This gives us the
probability of that question, when asked, ruling out a patient for a particular trial. So the
approach would be to ask the question which has the highest probability of ruling out a
patient first. When multiple trials are tested at once and same question is in the
acceptance expression of more that one trial, we add the separate probabilities of the
question for each trial. Note that the result of the summation can be greater then one, thus
it is not a probability anymore. Rather it is summation value which, when higher,
suggests a higher likelihood of determining a patient ineligible.
These probabilities are also used to estimate the eligibility probability. Here we
make an important assumption that all questions have independent probabilities.
Although this assumption is not entirely true, it seems close enough. Most questions are
either completely dependent on each other or are not at all dependent. For example if a
patient has no positive lymph nodes, that means that the cancer stage is either 0 or I. Thus
the two questions “Does the patient have positive lymph nodes?” and “What is the cancer
stage?” are dependent on each other. We can take care of such situations by an
implication sub-system. We can add implication rules in the system such as “If cancer
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stage 0 or I then it implies that patient has no positive lymph nodes”. When system has
information that the cancer stage is either 0 or I, the implication subsystem automatically
generates information that no lymph nodes are positive and the system does not ask for
that information. Thus, all such completely dependent questions are taken care of by the
implication subsystem. There are very few questions which have a partial implication,
like “If a patient is ER positive then there is an 80% chance of positive lymph nodes”.
We ignore such conditional probabilities among questions and treat all questions as either
completely dependent or independent.
When we assume all questions to be independent, the eligibility criteria for a
protocol becomes a set of independent questions which must have favorable answers for
a patient to be eligible. Also we have the probability of how many times a question, when
answered, was responsible for a patient being ineligible for a protocol. Thus we have
probability of each question being answered favorably for eligibility. A patient will be
eligible for a protocol when each answer is favorable. Thus the eligibility probability of a
protocol will be the product of the favorable probabilities of all questions. When a
question is answered and the answer meets the eligibility rules of the clinical trial, we can
exclude it from our product and thus we get the new eligibility probability. As more
questions answered fit the eligibility criteria, the eligibility probability increases. When a
question’s answer does not fit the eligibility profile, the patient becomes ineligible and
the eligibility probability becomes zero. When the patient becomes eligible the eligibility
probability is 1. The eligibility probability varies between 0 and 1 when the eligibility of
a patient is undecided.
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Although the above mentioned approach gave good results when the computed
probabilities were used to reorder questions (as discussed in the “Experiments and
Results” section), the probabilities computed were not normalized and thus were very
small numbers that did not give any meaningful feedback to the user. To compute
probabilities that provide meaningful feedback, the Naïve Bayes approach appeared to fit
well. We can think of the patient enrolment procedure as a classification problem. The
classification classes will be “Eligible” or “Ineligible”. The attributes will be the
questions and the values for the question are “Favorable for eligibility” or “Unfavorable
for eligibility” for each clinical trial. We have a probability for each question to be
favorable and unfavorable for each clinical trial. Thus we have a classification problem
where we have probabilities for the occurrence of each attribute value. To use Naïve
Bayes we also needed probabilities of occurrence of each classification type, which is
“Eligible” or “Ineligible” in our case. We modified the system so that for each clinical
trial, the system recorded how many patients were tested for that clinical trial and how
many patients were decided to be eligible and ineligible. Thus, we could now use Naïve
Bayes to calculate the eligibility probability of a patient with partial information.
Let us assume that we have a clinical trial T with three questions Q1, Q2 and Q3.
Out of 100 patients that were tested on the clinical trial, we found 40 to be eligible and 60
to be ineligible. Question Q1 as asked 90 times and it disqualified patients 10 times, Q2
was asked 80 times and disqualified patients 5 times, and Q1 was asked 70 times and
disqualified patients 15 times. Thus P(TE), the probability of patient being eligible for
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40
protocol T is 100 . P(Q1), the probability that questions Q1 is answered favorably for
80
75
55
clinical trial T is 90 . Similarly P(Q2) = 80 and P(Q3) = 70 .

So when we don’t have any information, i.e. we don’t have answers for any
40
questions, then the probability of a given patient being eligible for clinical trial T is 100 .

Now assume that we have answers to questions Q1 and Q2 and the answers are favorable
for eligibility. Thus the new eligibility probability will be P(TE | Q1, Q2). According to
Naïve Bayes:

P(TE | Q1 , Q 2 ) = P(TE ) P(Q1 | TE ) P(Q 2 | TE )
P(Q1 | TE)

is the probability that question Q1 was answered favorably for

eligibility given the fact TE, which means that patient is eligible for clinical trial T. Now,
if a patient is eligible for a clinical trial, all the questions must be answered favorably for
eligibility. Thus P(Q1 | TE) = 1. Similarly P(Q2 | TE) =1. Thus P(TE | Q1 , Q 2 ) = P(TE ).
As shown, P(TE | Q1, Q2 …. Qn) will always be P(TE) regardless of the number of
questions answered. Thus Naïve Bayes cannot be used in this case as the probabilities do
not change dynamically when the acquisition of new information. For enhancing the
estimation technique for the clinical trial probability, we then used Bayes rule. Using
Bayes rule
P(TE | Q1 , Q 2 ) =

P(TE ) P(Q1 , Q 2 | TE )
P(Q1 , Q 2 )

As explained before P(Q1, Q2 | TE) will be the probability that questions Q1, Q2 are
favorable for eligibility given that the patient is eligible for protocol T. If the patient is
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eligible then the questions answered will always be favorable and thus P(Q1, Q2 | TE) = 1.
Also we have assumed that all questions are independent and thus
P(TE | Q1, Q2) = P(TE | Q1) P(TE | Q2)
Substituting all this values, we get the new equation as
P(TE | Q1 , Q 2 ) =

P(TE )
P(Q1 ) P(Q 2 )

Substituting the values of P(TE), P(Q1) and P(Q2) we get the value 0.48 for the
equation. Thus after answering two questions Q1 and Q2, the eligibility probability of a
patient for clinical trial T is 48%.
The generic equations for eligibility probability for a clinical trial when we have
favorable answers for eligibility for n questions will be
P(TE | Q1 , Q 2 .........Q n ) =

3.4

P(TE )
P(Q1 ) P(Q 2 ) ..... P(Q n )

Testing System

Every time a new reordering agent is implemented or the current agent is modified, its
effectiveness needs to be determined. To obtain data that can be used to compare
different agents’ effectiveness, a certain number of patients need to be assigned to clinical
trials using the clinical trial assignment system that incorporates the reordering agents in
question. Performing the operation of repeatedly assigning numerous patients to clinical
trials using the system is a time consuming and labor intensive task. The manual data
entry required severely increases the time needed to perform such experiments and limits
the number of patients that can be tested. To overcome such shortfalls, a testing system
was developed.
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The testing system takes a list of patient names, a list of clinical trials and path to
the patient assignment system as its arguments. It then autonomously checks the
eligibility of the list of patients for the list of clinical trials using the assignment system
which is accessible at the path specified in the argument. The patients in the patient list
already have had their eligibility manually determined for a set of clinical trials. For each
such patient in the patient list, the testing system creates a new test-patient and attempts
to determine the eligibility of the patient for the list of clinical trials provided using the
clinical trial assignment system whose link is passed as a parameter. The clinical trial
assignment system reorders questions and presents the question list with the topmost
question being the most important, according to the reordering parameters. The testing
system answers the topmost question of that list, by obtaining the answer from the
patient’s data that was manually added into the system. After the answer is obtained, the
clinical trial assignment system regenerates the reordering parameter values and reorders
the questions.
At the end of the execution, the testing system generates a summary file which
contains information for each patient such as the number of questions asked, cost,
eligibility status of the clinical trials, etc. Thus the testing system makes it fast, effective
and easy to test different heuristics without human intervention. The testing system works
autonomously, but it requires human intervention in certain cases. When the clinical trial
assignment system presents the reordered questions list and the testing system does not
have the answer to the topmost question on the list, it requires human intervention to find
out the answer to the question. This generally happens because the original patient data
do not contain answers for all questions. The clinical trial assignment system stops
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presenting further questions for a trial when the patient is either eligible or ineligible for
that trial. So a patient’s data generally do not contain answers to all the questions. When a
new heuristic is implemented, questions are reordered differently and often a question
which is unanswered in the original patient data is presented. The testing system would
not be able to find data for it and thus it seeks human intervention. In the summary file,
all such patients are listed. A user can then look at medical database of the hospital or
patient’s chart to obtain the information and enter it into the system.
The code for the testing system is written in PERL, while the rest of the system is
coded in C. The code can be found in the CD ROM presented with the thesis.
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Chapter 4
User Interface
4.1

Interface Design

The system provides a user-friendly web-based interface for the user. The whole system
is designed in such a way that there is a central system and clinical personnel can access
it from anywhere via the internet. A user can enter new patients and check their eligibility
for all the available trials. Figure 7 shows the control flow diagram of the user interface.

Revising test data

• View test status
• Change test status

Adding patients

• Add a new patient
• Find an old patient

Selecting clinical trials

• Choose candidate trials
• View available trials

Entering initial data

• Answer initial questions
• Change previous answers

Entering medical data

• Enter test results
• View eligibility decisions

Revising medical data

• View test results
• Change some results

Figure 7: User Interface Design
The user starts by entering the name and identification number for the patient as
shown in Figure 8. The combination of name and identification number should be unique
for all the patients. The user also has search options to find patients whose data was
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entered previously and may resume entering data for them. There is an option to optimize
cost or data entry when testing. As shown in Figure 8, if the user selects “Cost Version”,
cost is optimized and if the “No Cost Version” is selected, data entry is optimized.

Figure 8: Initial Patient Entry Page

Figure 9: Initial Questions Page
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After the patient’s name and identification are added, the system presents 14
initial questions as shown in Figure 9. These are general information questions like
patient’s age, sex, etc. and are generally used in most of the clinical trials. After the user
has entered the initial information, the next screen is a list of available trials for which the
patient’s eligibility can be checked. At least one of the clinical trials must be selected. In
Figure 10 five clinical trials of the available 17 were selected.

Figure 10: Clinical Trial Selection Page
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The system then checks the eligibility of the patient for the selected trials. If it
needs more information to determine the eligibility then it makes a list of missing
information questions and reorders the questions optimizing cost or data-entry as selected
by the user. It then presents the top ten questions of the reordered question list on the next
page as shown in Figure 11.

Figure 11: Data Entry Page. The System Asks for More Information to Determine
Patient's Eligibility.
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Figure 12: Status of all Clinical Trials

At any time the user can check the eligibility status of the clinical trials by
clicking the drop down box as shown in Figure 12. The system keeps on presenting
questions until the eligibility of all the clinical trials for the given patient is known. The
user can stop entering data at any point. Data entry for the patient can be reinitiated at any
later time by using the search option shown in Figure 8.

27

Figure 13: Explanation of a Decision by Explanation Sub-System

At any time you can click on why button and the explanation sub-system will
justify the system’s decisions as shown in Figure 13. Figure 14 appears when the
patient’s eligibility for all the clinical trials is decided and there is no more information
needed.

Figure 14: System after Eligibility of all Clinical Trials is Decided
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Figure 15: Status of all Available Tests for the Patient

At any time you can also check the status of the tests know for the current trials. Figure
15 shows the test status of all the tests for the given patient. There are three statuses for
the tests: a) Done before, b) Done, and, c) Not done. “Done before” means that the test
was already done before the patient was checked for enrollment in a clinical trial. This
gives the correct cost incurred for determining eligibility for the patient as the system will
not count the cost of such tests in total cost for the patient. “Done” tests are the ones done
to obtain more information to decide a patient’s eligibility for clinical trials. Similarly
“Not done” are the tests that are available in the system but are still not done for the
patient. At any point the user can change the status of any test.
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Chapter 5
Experiments and Results
5.1

Analytical Experiments

Data of patients treated at the Moffitt Cancer Center was used to compare the system’s
results with that of clinicians. Results from the application of various heuristics are also
compared. The first set of experiments were done on retrospective data from 187 patient
charts. Table 1 shows the comparison of automated assignment by the system and manual
assignment by clinicians at Moffitt Cancer Center. These experiments were started by
Kokku [33]. The results are also published in IEEE SMC 2003 conference [14].

Table 1: Results of Matching Retrospective 187 Patients to Clinical Trials
Clinical
Trial
10822
10840
11072
11378
11992
12100
12101

Same
Matches
10
0
48
4
5
8
20

New
Matches
5
19
26
19
6
20
30

Missing
Data
0
3
19
3
0
13
0

Table 1 shows the number of patients that were eligible for a particular trial. “Same
Matches” column indicates the patients who were found eligible by the system and were
also found eligible by the clinicians. The “New Matches” column indicates the patients
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who were found eligible by the system but were potentially missed by the clinicians. The
“Missing Data” column indicates the patients that did not have enough information to
determine their eligibility. All the patients are not tested for all the clinical trials and thus
some of them do not have some tests performed that are essential to determine eligibility
for a specific clinical trial. Also the data was retrospective, thus the patients were not
undergoing treatment at the Moffitt Cancer Center.
Some questions, which were generally consent-based questions, were answered
“Yes” while performing the experiments as we had no actual way to determine their
answers. Below are a few such questions:
1. Is the patient willing to sign the consent form?
2. Does the patient have at least sixth grade education?
3. Is the patient willing to use contraceptives?
The next set of experiments were done on 169 patients who were getting treatment at
Moffitt Cancer Center at the time of experiments. The results are shown in Table 2.
Table 2: Results of Matching Current 169 Patients to Clinical Trials
Clinical
Trial
11132
11931
11971
12100
12101
12385
12601
12643
12757
12775

Number of
Tested
Patients
7
169
159
162
166
42
162
63
58
133

Same
Matches
4
2
4
0
11
0
0
18
1
23
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Missing
Info
1
5
0
0
6
0
3
2
4
6

New
Matches
1
26
0
5
52
19
1
34
3
17

Table 3: Detailed Classification of New Matches Found

Clinical
Trial

New
Matches

New
Matches
with no
enrollment

11132
11931
11971
12100
12101
12385
12601
12643
12757
12775

1
26
0
5
52
19
1
34
3
17

0
15
0
4
33
9
1
24
2
11

New
Matches
with no
conflict

New
Matches
with
conflict

% of
"Assignable"
New Matches
over number of
checked patients

1
11
0
1
6
2
0
10
1
3

0
0
0
0
13
8
0
0
0
3

14.29%
15.38%
0.00%
3.09%
23.49%
26.19%
0.62%
53.97%
5.17%
10.53%

% of "Actual"
Enrollment
over number
of checked
patients

57.14%
1.78%
2.52%
0.00%
6.63%
0.00%
0.00%
30.16%
1.72%
18.80%

Table 2 is similar to Table 1 which was explained previously. Table 3 categorizes the
new matches found by the system. The third column of Table 3 specifies the number of
new matches in which the patient was not enrolled in any clinical trial. Thus this number
represents the patients who were found eligible for some clinical trial by the system, but
were never enrolled in any clinical trial by the clinicians. The fourth column indicates the
number of matches in which the patient was assigned to a clinical trial but there was still
a clinical trial to which she could be assigned. Many clinical trials are compatible and
thus a patient can be in two clinical trials at once. Such clinical trials are called
compatible clinical trials. Thus the numbers in fourth column indicates the patients who
were assigned to a clinical trial but there was an available compatible clinical trial to
which they were not assigned. The fifth column indicates the number of matches found in
which the patient was already enrolled in an incompatible trial. Thus this match has no
significance as the patient could not have been assigned to the matching trial anyway.
The sixth column indicates the percentage of assignable matches found over the number
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of patients checked. The number of assignable matches found, is the summation of the
third and fourth columns. This indicates the matches in which the patient could have been
safely enrolled in a new clinical trial to which the patient was not previously assigned.
The last column is the percentage of actual enrollment in that clinical trial. Note that in
the majority of protocols, the percentage of new assignable matches found is greater than
the actual enrollment.
The results clearly show that the system was able to detect many matches which
were potentially missed by clinicians. Given that fact that many clinical trials fail due to
under-recruiting [11, 22, 33], the system can potentially play a crucial role in the success
of a clinical trial.
5.2

Cost Saving Experiments

In case of lack of information to determine a patient’s eligibility for a clinical trial, the
clinicians order specific tests to be performed on the patient to obtain relevant
information. Research suggests that test costs can be saved if we optimize the test
ordering [1, 11, 14]. The system’s reordering agent reorders the questions presented by
the system to the user. This, in turn, results in reordering of the tests as tests needs to be
performed to obtain answers to the questions. Reordering heuristics were designed to
optimize the cost as explained in the system design section. Tables 4 and 5 show the cost
saving information for the retrospective 183 patients and current 169 patients
respectively.

33

Table 4: Average Dollar Cost Savings for 187 Retrospective Patients
Average Dollar Cost
Without Test
With Test
Reordering
Reordering
$70
$11
$0
$0
$209
$60
$35
$19
$0
$0
$0
$0
$0
$0

Clinical
Trial
10822
10840
11072
11378
11992
12100
12101
$250

Average Cost

$200
$150
$100
$50
$0
10822

11072

11378

Protocol
Without Test Reordering

With Test Reordering

Figure 16: Graph Showing Average Dollar Cost Savings for Retrospective Patients
Table 5: Average Dollar Cost Savings for 169 Current Patients
Clinical
Trial
11132
11931
11971
12100
12101
12385
12601
12643
12757
12775

Average Dollar Cost
Without Test
With Test
Reordering
Reordering
$0
$0
$0
$0
$192
$192
$0
$0
$0
$0
$0
$0
$36
$3
$0
$0
$107
$107
$0
$0
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$250

Average Cost

$200
$150
$100
$50
$0
11971

12601

12757

Protocol
Without Test Reordering

With Test Reordering

Figure 17: Graph Showing Average Dollar Cost Savings for Current Patients

5.3

Probabilistic Experiments

It was noted that medical test results were highly probabilistic in nature. Most test results
can be estimated with reasonable accuracy before the test is performed. Given enough
data this knowledge can be used to reorder tests and to optimize data entry needed to
determine the eligibility of a patient. Also it was noted that over time, clinicians typically
get a good estimate of what information is likely to be most crucial in determining the
eligibility of a patient and prefer to get that information first. We developed a
probabilistic knowledge base on the same principles. Whenever a question is answered
by a user, the system records it. If answering the question made a patient ineligible for a
clinical trial, this is recorded too. Thus we get a basic ratio of the number of times a
question was asked, to the number of times it made a patient ineligible for a particular
protocol. Treating this as a probability we reorder the questions, with the questions
having a higher probability of ruling a patient out of a clinical trial being asked first. The
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idea is that if a patient is ineligible then the question which is most likely to determine
she is ineligible, from past experience, is asked first and this will reduce data entry. This
method also closely mimics the method adopted by clinicians and thus can increase
acceptability of the system by medical personnel.
The system begins by assigning a 50% probability to all the questions. The
probability is modified as the system sees new evidence. To test the effectiveness of this
technique we did a ten-fold cross validation. We randomly selected 90% of the patients
and their data was used to generate a probabilistic knowledge base for the system. The
remaining 10% of the patients were tested using the system which used this probabilistic
knowledge base to reorder the questions. This process was repeated ten times with each
10% of the testing patients being unique. Six clinical trials were used in the experiments.
These six clinical trials were selected out of about 15 possible clinical trials, as these
trials were in “open” status for a long enough duration during the experiments to have an
adequate number of patients being tested for those clinical trials. In the probabilistic
experiments it was necessary to train the system on an adequate number of patients
before it can be used to reorder questions for other patients. We selected 90 patients at
random from our list of patients and used their data in experiments. As mentioned above,
a ten-fold cross validation was carried out, so that the system was trained on 81 patients
and the remaining 9 patients were tested using the system.
Table 6 shows the results of each fold of the cross validation. Table 7 shows
results of the cross validation per clinical trial.
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Table 6: Individual Test Results for Ten-Fold Cross Validation

Test
Number
1
2
3
4
5
6
7
8
9
10
Total

Ten-fold cross validation
Average number of questions
Probabilistic
Analytical
System
System
Difference
16.67
20.75
4.08
15.17
17.00
1.83
15.83
17.58
1.75
15.75
18.25
2.50
13.83
16.67
2.83
15.58
17.75
2.17
15.83
18.25
2.42
15.50
16.83
1.33
16.50
18.50
2.00
15.83
19.17
3.33
15.65
18.08
2.43

Difference
%
19.68
10.78
9.95
13.70
17.00
12.21
13.24
7.92
10.81
17.39
13.42

Table 7: Results of Ten-Fold Cross Validation per Protocol

Protocol
11931
12100
12101
12521
12601
12777
Average

Ten-fold cross validation
Average number of questions
Probabilistic
Analytical
System
System
Difference
15.35
18.90
3.55
13.85
13.95
0.10
21.65
24.75
3.10
14.75
19.05
4.30
13.90
15.70
1.80
14.40
16.10
1.70
15.65
18.08
2.43

Difference
%
18.78
0.72
12.53
22.57
11.46
10.56
13.42

As seen in Table 7 the probabilistic system reduces data entry by 13.42% on average as
compared to the analytical system. The average number of questions asked by the system
is reduced by 2.43. One important observation is that the probabilistic system always
asks fewer questions than the analytical system for all the patients tested. Using the t-test,
the probabilistic system is statistically significantly better at the 99.99% confidence
interval.
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Table 8: Standard Deviation for Ten-Fold Cross Validation
Standard deviation
New
No Cost
Protocol
System
Version
11931
7.44
6.11
12100
1.39
1.61
12101
7.44
6.11
12521
5.39
6.54
12601
3.67
5.55
12777
5.69
7.26

Also note that as shown in the system’s interface design diagrams, the system asks 14
basic questions after one enters a patient into the system. These questions are general
questions which are used in almost all trials, like patient’s age, sex, etc. If the patient’s
eligibility is still not determined for all the trials for which her eligibility is tested, the
system asks for further information. Thus technically you answer a minimum of 14
questions for a patient as it is very unusual to not to have information about any of those
questions. For such patients who get ruled out of a clinical trial after the questions on the
initial page, the number of questions asked in both the systems remains the same as there
is no reordering of questions. Table 9 shows the average number of questions when we
exclude such patients from our experiment. The probabilistic system asks 3.69 fewer
questions on an average than analytical system which is 18.53% less then analytical
system. It saves up to 33% of the data entry for 12601, which is the maximum.

38

Table 9: Results Excluding Patients who were Ineligible by Initial Questions

Protocol
11931
12100
12101
12521
12601
12777
Average

5.4

Ten-fold cross validation
Average number of questions
Probabilistic
Analytical
System
System
Difference
16.71
21.79
5.07
14.75
15.25
0.50
22.05
25.32
3.26
14.75
19.05
4.30
14.60
21.80
7.20
14.42
16.21
1.79
16.21
19.90
3.69

Difference
%
23.28
3.28
12.89
22.57
33.03
11.04
18.53

Eligibility Probability

A major disadvantage of using an analytical approach to finding eligibility is that even in
the absence of a single piece of evidence, we cannot predict anything about the eligibility
of a patient. On the other hand, with a probabilistic approach, we can make some
predictions about the eligibility. Papaconstantinou [10] showed in his experiment that by
using Bayesian Networks, we can determine a patient’s eligibility in the absence of some
evidence. In our rule based system, we tried to use the independent probabilities that we
had for each question, to generate a prediction about a patient’s eligibility probability in
the absence of evidence. As explained before in the system design section, we assume
that all questions are independent, so the eligibility probability for a protocol is the
product of the individual probabilities that a question does not rule out a patient, of all the
questions of that protocol. As we enter more information in the system, if the patient is
ruled ineligible by the system, her eligibility is 0, and if she is eligible then her eligibility
probability is 1. If we still need more information, we recalculate the eligibility
probability as the product of eligibility probability of all the unanswered questions.
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One of the uses of the eligibility probability can be to try to quickly assign a
patient to a clinical trial. This can be achieved by generating an initial eligibility
probability for all the available trials for that patient. We then check the eligibility of the
patient for the trial which has the highest eligibility probability. After every piece of
information, the probabilities are regenerated and the system asks for more information
about the trial with the highest eligibility probability until the patient is found eligible for
a trial or is determined ineligible for all the trials. The system stops seeking further
information after the patient is found eligible for a clinical trial as the purpose of these
experiments is to find a single matching protocol with least the number of questions
being answered. To test the effectiveness of this approach we did a ten-fold cross
validation on the available patients using this approach. We used six clinical trials. We
compare the results with the analytical system in which we stop answering questions
when it finds a clinical trial for which the patient is eligible. Results are shown in Table
10.
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Table 10: Ten-Fold Cross-Validation for Heuristic that Uses Eligibility Probability

Test
Number
1
2
3
4
5
6
7
8
9
10
Average

Ten-fold cross validation
Average number of questions
Probabilistic
Analytical
System
System
Difference
22.33
28.67
6.33
30.67
34.33
3.67
31.33
24.33
-7.00
30.00
33.00
3.00
19.67
25.00
5.33
20.67
31.67
11.00
28.33
33.00
4.67
24.00
36.67
12.67
21.67
22.67
1.00
17.67
24.33
6.67
24.63
29.37
4.73

Difference
%
22.09
10.68
-28.77
9.09
21.33
34.74
14.14
34.55
4.41
27.40
16.12

As shown in Table 10, using the eligibility probability in reordering heuristic saves
16.12% of data entry. For the third test in ten-fold cross validation, the probabilistic
system asks more questions then the analytical system. This is because the protocols for
which the patient is more likely to be eligible are tested first in the probabilistic system
and the patients were ineligible for that protocol. Thus the number of questions asked
increases as compared to the analytical system. Using the t-test, the probabilistic system
is statistically significantly better at the 95% confidence interval.
Although the method gave good results, it had an inherent drawback that the
probabilities were not normalized and thus the resultant probabilities were a very low
number that were inappropriate for providing feedback to users. As discussed in the
“System Design” section, we used Bayes probabilities to compute probabilities that were
more suitable to give appropriate feedback. The same set of 90 patients that were used in
the previous experiments were used to conduct 10-fold cross validation experiments.
Figure 11 shows the results.
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Table 11: Ten-Fold Cross-Validation for Reordering Agent that Uses the Bayes Method
to Compute Eligibility Probability

Test
Number
1
2
3
4
5
6
7
8
9
10
Average

Ten-fold cross validation
Average number of questions
Probabilistic
Analytical
System
System
Difference
20.67
29.00
31.67
26.33
22.33
18.67
25.67
22.67
19.33
17.33
23.37

28.67
34.33
24.33
33.00
25.00
31.67
33.00
36.67
22.67
24.33
29.37

8.00
5.33
-7.33
6.67
2.67
13.00
7.33
14.00
3.33
7.00
6.00

Difference
%
27.91
15.53
-30.14
20.20
10.67
41.05
22.22
38.18
14.71
28.77
20.43

The results show that Bayes method of computing eligibility probability and using
it in reordering the questions reduces the data entry needed by 20.43 % on an average.
Also the probabilities generated were more appropriate for feedback as the probabilities
computed were real probabilities unlike the previous method where they were not
normalized and thus were very small numbers. Using the t-test, the probabilistic system
is statistically significantly better at the 95% confidence interval.
As shown by the results, the reordering agent using Bayes method for computing
eligibility probability reduces data entry more then the reordering agent using the
previous method. Although the Bayes method is know to provide with more accurate
probability, the previous method was tried as it had an important feature that the
eligibility probability was dependent on the number of questions in the clinical trial. As
the individual probabilities of each question was very small number, the more questions
in the eligibility probability, the lesser the eligibility probability gets as it was the product
of individual probability of each question. This method is biased towards the clinical
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trials with lesser number of questions, which can help optimize data entry. Out of the six
clinical trial used in the experiments, clinical trial number 12777 has four questions and
clinical trial 12521 have 34 questions. Is such a scenario it might be optimal to check the
eligibility of clinical trial 12777 before 12521 even if 12521 has higher rate or
enrollment. If 12521 have better rate or enrollment then 12777 then the reordering agent
using Bayes method for calculating eligibility probability will estimate a higher eligibility
probability for 12521 and ask for more information about that clinical trial. Whereas, the
reordering agent that estimates eligibility probability by product of individual questions
will most certainly estimate a higher eligibility probability for 12777. The experiment
results suggest that when the reordering agent uses Bayes method to estimate eligibility
probability, it results in a more data entry efficient agent.
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Chapter 6
Conclusions and Future Work
6.1

Conclusions

Recruiting patients to clinical trials is very time and labor intensive work. Many clinical
trials fail due to under recruitment. The system presented here has found a substantial
number of matches potentially missed by clinicians. Thus the system can play a critical
part in the success of a clinical trial. Also the web-based interface of the system makes it
possible to have a central system which can be accessed by clinical personnel from any
medical institute around the country. All large research centers have clinical trials of their
own and it is very hard to exchange the trial information between them as the same trials
can be interpreted in a different way by different clinicians. Having an electronic version
of the clinical trials encoded using our knowledge entry system can make sharing of
clinical trials between different hospitals very convenient and effective. This in turn can
increase accrual for clinical trials as the pool of potential participants increases.
The system also effectively reorders the tests and reduces the cost incurred in
determining eligibility.

We developed the probabilistic agent which accumulates

probabilistic knowledge over time. Data entry was successfully optimized by as much as
30% using the probabilistic reordering agent. The testing system makes it possible to
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efficiently check the performance of different reordering heuristics. The system also
mimics human behavior which may increase its acceptability to medical personnel.
6.2

Future Work

The system was designed to match patients to clinical trials of any kind, but currently
only breast cancer clinical trials are being implemented. The system currently reorders to
optimize cost and data entry but it also has provisions to incorporate pain measures for
each test and reorder to minimize pain for the patients. These options still need to be
explored.
The probabilistic reordering agent use independent probabilities of each question
and estimate eligibility probability using Bayes rule . Other probabilistic methods need to
be explored to try to improve the reordering and save more data entry and costs. In the
experiments conducted, the probabilistic agents were trained on 81 patients. The
effectiveness of the agents needs to be investigated when different number of patients are
used in training.
The system currently is a web-based CGI application. Thus every time the system
is accessed, it has to regenerate all the graphs and load parts of knowledge into memory.
Currently we are implementing a port-listening version of the system, which keeps all the
graphs and needed knowledge in memory until needed. This will eventually improve the
responsiveness of the system even when the patient is being tested for a large number of
clinical trials at once.
The reordering heuristics either use the probabilistic or the analytical approach.
Heuristics that use both approaches together still need to be implemented and tested.
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